Actively Recruiting

Phase 1
Age: 18Years +
All Genders
NCT06439914

First-in-human Study of Interferon-y PET Imaging to Assess Response to Immunotherapy

Led by Nerissa T. Viola · Updated on 2026-03-11

6

Participants Needed

1

Research Sites

168 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The goal of this clinical trial is to investigate the use of \[89Zr\]Zr-DFO-emapalumab as an IFN-γ PET imaging agent to detect lesions and response to therapy among treatment-naïve non-small cell lung cancer (NSCLC) patients. PET scans following the imaging agent will be completed prior to and about 30 days after starting immunotherapy.

CONDITIONS

Official Title

First-in-human Study of Interferon-y PET Imaging to Assess Response to Immunotherapy

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Prior histologic or cytologic diagnosis of non-small cell lung cancer.
  • FDG PET done within 2 months of the baseline imaging, as part of standard-of-care.
  • Measurable disease by RECIST 1.1 with at least one lesion of at least 2 cm in a region of the body that can be imaged by PET (e.g., outside of the liver).
  • Ability to lie still for the tests and suitable girth and weight to enter the scanner gantry.
  • Age over 18 years.
  • Signed informed consent acknowledging the investigational nature of the study.
  • Physical exam, CBC, and multiphasic blood tests (including electrolytes, BUN, creatinine, total bilirubin, AST, and ALT) done within 28 days prior to PET imaging.
Not Eligible

You will not qualify if you...

  • No prior immunotherapy for current stage of NSCLC; prior immunotherapy in neoadjuvant or adjuvant setting is allowed if recurrence is at least 12 months after completion and approved by the principal investigator.
  • Pregnant or breastfeeding individuals.

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Karmanos Cancer Institute

Detroit, Michigan, United States, 48201

Actively Recruiting

Loading map...

Research Team

N

Nerissa T Viola, PhD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

DIAGNOSTIC

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

First-in-human Study of Interferon-y PET Imaging to Assess Response to Immunotherapy | DecenTrialz